title: The dark side of dopaminergic therapies in Parkinson's disease: shedding light on aberrant salience.
abstract: Psychotic subjects and patients with Parkinson's disease (PD) "on" dopaminergic drugs, especially on dopamine agonists, present a hyperdopaminergic state that interferes with learning processing. These clinical populations present with distinct alterations of learning that share an increased potential motivational significance of stimuli: psychotic subjects may attribute salience to neutral stimuli, while medicated PD patients may overvalue rewards. Herein is discussed the speculative hypothesis that the hyperdopaminergic state induced by dopaminergic treatments, especially with dopamine agonists, may also facilitate the attribution of salience to neutral stimuli in PD patients, altering the physiological attribution of salience. Preliminary empirical evidence is in agreement with this speculative hypothesis, which needs further empirical investigation. The clinical implications of this hypothesis are discussed in relation to behavioral addictions, psychosis proneness, and enhanced creativity in medicated PD patients.
authors.affiliation: Department of Mental Health and Pathological Addiction,Azienda Unità Sanitaria Locale Reggio Emilia,Reggio nell'Emilia,Italy.
authors.forename: Michele
authors.initials: M
authors.lastname: Poletti
mesh_terms: D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007175:Impulsive Behavior / Q000187:drug effects; D007858:Learning / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D018491:Dopamine Agonists
keywords: Dopamine agonists; aberrant salience; creativity; impulse control disorders; psychosis